Advances in iron chelating therapy

Haematologica

Volumn 85, Issue 11, 2000, Pages 1122-1125

  Franchini, M ^a   Gandini, G ^a   Aprili, G ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; HETASTARCH;

DRUG FORMULATION; DRUG TOLERABILITY; EDITORIAL; HUMAN; IRON CHELATION; IRON OVERLOAD; PATIENT COMPLIANCE;

DEFEROXAMINE; DRUG ADMINISTRATION ROUTES; DRUG THERAPY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 0033650606     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (40)

1. Survival and disease complications in thalassemia major
2. Classification and diagnosis of iron overload
3. Iron excretion in thalassemia major after administration of chelating agents
4. Reassessment of the use of desferrioxamine B in iron overload
5. Continuous subcutaneous administration of deferoxamine in patients with iron overload
6. The management of iron chelation therapy
7. Desferrioxamine-induced iron excretion in humans
8. Current status of iron chelation therapy with deferoxamine
9. Thalassemia: Clinical management
10. Iron chelating therapy
11. The thalassemias
12. Chelation therapy in β-thalassemia: The benefits and limitations of desferrioxamine
13. A risk-benefit assessment of iron-chelation therapy
14. Iron-chelation therapy and the treatment of thalassemia
15. Iron chelators for thalassemia
16. Results of long-term iron-chelating therapy
17. An alternative method of subcutaneous deferoxamine administration
18. Evaluation of a new method of administration of the iron chelating agent deferoxamine
19. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematological diseases and iron overload
20. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassemic patients
21. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassemic patients
22. Efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
23. Relative efficacy of subcutaneous infusion and bolus injections of deferoxamine in the removal of non-transferrin-bound iron (NTBI)
24. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
25. Studies of iron excretion and non-transferrin-bound plasma iron following a single infusion of hydroxyethyl starch-deferoxamine: A new approach to iron chelation therapy
26. Iron balance and chelation efficacy following single dose depot desferrioxamine
27. A depot formulation of desferrioxamine (ICL749B): Update on the dose-finding program
28. Oral iron chelation
29. Deferiprone. A review of its clinical potential in iron overload in thalassemia major and other transfusion-dependent diseases
30. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
31. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
32. Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study
33. Iron balance in thalassemia patients treated with deferiprone
34. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
35. Liver assessment in a group of transfusion dependent patients treated with deferiprone and compared to a group of patients treated with desferrioxamine
36. Iron chelation with oral deferiprone in patients with thalassemia
37. Iron chelation with oral deferiprone in patients with thalassemia
38. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
39. Long-term follow up of growth, bone and cartilage abnormalities during chelation therapy with deferoxamine and deferiprone
40. Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO)